Point-of-care diagnostics provider EKF Diagnostics is showcasing a novel test that the company asserts can accurately identify diabetic patients at high risk of progression to end stage renal disease (ESRD) up to 10 years in advance of currently available tests. The new sTNFr1 test was highlighted at the just-completed American Diabetes Association (ADA) annual meeting.
The sTNFr1 test detects circulating levels of Soluble Tumor Necrosis Factor receptor 1 (sTNFr1) in patient samples. Recent research has demonstrated that high circulating levels of sTNFr1 are strongly associated with progression to ESRD in patients both with and without overt nephropathy.
EKF representatives told ADA conference attendees that the sTNFr1 test is an easy-to-use microtiter plate assay requiring minimal training. Standard laboratory equipment can be used to analyze just 50 µL of blood serum or plasma. The assay uses monoclonal antibodies to give accurate and reliable results in a few hours and has minimal interference and no cross-reactivity with sTNFr2.
EKF also demonstrated its STAT-Site M meter for quantitative determination of ß-Hydroxybutyrate (ß-HB). The STAT-Site M ß-HB system is composed of a reflectance photometer and dry-reagent strip for rapid and accurate detection of ß-HB. Knowing exact ß-HB levels offers useful clinical information for monitoring diabetic ketoacidosis (DKA) in newly diagnosed patients and for reducing time and cost in an intensive care unit. Read more about EKF Diagnostics’ range of diabetes related tests and point-of-care devices.